Fundraising Fox
/Companies
Sign in

Aurealis Pharma

Founded 2015 · 4 known investors

Find your way into Aurealis Pharma

563 people in our graph can introduce you to the Aurealis Pharma team.

Sign up to see every warm intro you have to Aurealis Pharma

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Aurealis Pharma team. We find them
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes you can't see from your own inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

Aurealis Therapeutics is a Swiss-Finnish clinical-stage company developing multi-target bacterial gene therapies based on genetically engineered Lactococcus cremoris, using a modular platform that produces multiple human therapeutic proteins directly in diseased tissue. Its therapies target chronic wounds, cancer, and inflammatory diseases, with a lead product for diabetic foot ulcers.

BiotechDeep TechHealthtechMedical Devices

Founders & leadership

Aurealis Pharma was founded in 2015 by Juha Yrjänheikki.

JYJuha Yrjänheikki
Juha YrjänheikkiCEOJuha Yrjänheikki holds an MSc in biotechnology (molecular biology, 1997) and a PhD in neuroinflammation of stroke and ischemia (2000), both from the University of Kuopio, and was previously a research scientist at the A.I. Virtanen Institute and a visiting researcher at Stanford University's Department of Neurosurgery. He is CEO and co-founder of Aurealis Therapeutics AG, having earlier led Aurealis Pharma AG, Charles River Discovery Services Finland, and Cerebricon Ltd, and held board and investment roles at Nostetta Ventures and other biotech ventures, alongside a stint as Professor of Practice at the University of Eastern Finland (2018–2021).
LDLaurent Décory
Laurent DécoryCOOLaurent Décory holds an MBA from ESSEC Business School and a PhD in Neurosciences and Pharmacology from the University of Bordeaux. He serves as Chief Operating Officer of Aurealis Therapeutics, overseeing business development, health economics, alliance management, and marketing for the company's clinical-stage bacterial gene therapy platform.
HPHanna P. Lesch
Hanna P. LeschChief Technology OfficerHanna P. Lesch is Chief Technology Officer at Aurealis Therapeutics, where she leads technology strategy, manufacturing, and process development for bacterial gene therapies. She previously held CTO and director-level roles at Exothera, FKD Therapies, Finvector, and the Kuopio Center for Gene and Cell Therapy, with expertise in gene therapy development and bioprocessing; she holds a PhD in Molecular Medicine and completed postdoctoral research at UCSD and the University of Eastern Finland.

Investors · 4

Nostetta Ventureslisted by Nostetta VenturesKuopiovia Minna Vanninen · inferred

Also in the syndicate · 2

Finnvera plcTekes – the Finnish Funding Agency for Innovation

Funding

SEC filings, press & company announcements
  • Undisclosed amountSeries AAug 2017

    Finnvera plc, Tekes – the Finnish Funding Agency for Innovation

    Source ↗

Source: company announcements and press reports — follow each round's link for the claim.

In the news

Aurealis Pharma Announces 5.6MCHF Series A Financing To Advance Chronic Wound And Oncology Lead Products - BioSpacebiospace.com · Aug 2017

Frequently asked questions

What does Aurealis Pharma do?
Aurealis Therapeutics is a Swiss-Finnish clinical-stage company developing multi-target bacterial gene therapies based on genetically engineered Lactococcus cremoris, using a modular platform that produces multiple human therapeutic proteins directly in diseased tissue. Its therapies target chronic wounds, cancer, and inflammatory diseases, with a lead product for diabetic foot ulcers.
Who founded Aurealis Pharma?
Aurealis Pharma was founded by Juha Yrjänheikki in 2015.
Who are Aurealis Pharma's investors?
Aurealis Pharma's investors include Innovestor Ventures, Nostetta Ventures.